Phaseline

Companies › Hunan Kelun Pharmaceutical

Hunan Kelun Pharmaceutical: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 1; Other; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KL0011034 injection–Phase 1Healthy VolunteersDec 2027
KLA318-2 Nanocrystal Injection–Phase 1Healthy Participants–
KLA478–Phase 1Healthy Volunteers–
KLA578-1 for injection–Phase 1Healthy Volunteers–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07143318KLA578-1 for injectionPhase 1Healthy VolunteersOtherMay 2026
NCT07171034KLA318-2 Nanocrystal InjectionPhase 1Healthy ParticipantsOtherMay 2026
NCT07240675KLA478Phase 1Healthy VolunteersOtherSep 2026
NCT07474545KL0011034 injectionPhase 1Healthy VolunteersOtherDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.